A case report on sorafenib induced adverse reaction

Irfan M. G. Khan; Sunil K. Nayak; Divyasri G.; Abhinay K.; Srideep D.

doi:10.18203/issn.2454-2156.IntJSciRep20191861

Authors

Irfan M. G. Khan Department of Oncology/Hematology, Chalmeda Anandrao Institute of Medical Sciences (CAIMS), Cancer Hospital and Research Institute, Karimnagar, Telangana
Sunil K. Nayak Department of Clinical Pharmacy, Vaageswari College of Pharmacy, Karimnagar, Telangana
Divyasri G. Department of Clinical Pharmacy, Vaageswari College of Pharmacy, Karimnagar, Telangana
Abhinay K. Department of Clinical Pharmacy, Vaageswari College of Pharmacy, Karimnagar, Telangana
Srideep D. Department of Clinical Pharmacy, Vaageswari College of Pharmacy, Karimnagar, Telangana

DOI:

https://doi.org/10.18203/issn.2454-2156.IntJSciRep20191861

Keywords:

Sorafenib, Hand-foot syndrome, Renal cell carcinoma, Hepatic cell carcinoma, Multi kinase inhibitor

Abstract

Sorafenib is an oral multi-kinase inhibitor used primarily in the treatment of hepatic cellular carcinoma, renal cell carcinoma, and thyroid carcinoma. Hand-foot syndrome also is known as palmar-plantar erythrodysesthesia causes reddening, numbness, swelling of palms of hands and soles of feet. In this report, a known case of renal cell carcinoma, post right nephrectomy patient on treatment with tab sorafenib had developed the hand-foot syndrome.

Metrics

Metrics Loading ...

References

Sil A, Das NK. Sorafenib-induced hand-foot syndrome in a patient of renal cell carcinoma. Indian J Pharmacol. 2014;46(3):334–6.

Lee JH, Chung YH, Kim JA, Shim JH, Lee D, Lee HC, et al. Genetic predisposition of hand‐foot skin reaction after sorafenib therapy in patients with hepatocellular carcinoma. Cancer. 2013;119(1):136-42.

Gomez P, Lacouture ME. Clinical presentation and management of hand–foot skin reaction associated with sorafenib in combination with cytotoxic chemotherapy: experience in breast cancer. The Oncologist. 2011;16(11):1508-19.

Azad NS, Aragon-Ching JB, Dahut WL, Gutierrez M, Figg WD, Jain L, et al. Hand-foot skin reaction increases with cumulative sorafenib dose and with combination anti-vascular endothelial growth factor therapy. Clin Cancer Res. 2009;15(4):1411-6.

Available at: https://www.drugbank.ca/drugs/ DB00398. Accessed on 3 January 2019.

Available at: https://www.cancer.net/navigating-cancer-care/side-effects/hand-foot-syndrome-or-palmar-plantar-erythrodysesthesia. Accessed on 3 January 2019.

Kang YK, Lee SS, Yoon DH, Lee SY, Chun YJ, Kim MS, et al. Pyridoxine is not effective to prevent hand-foot syndrome associated with capecitabine therapy: results of a randomized, double-blind, placebo-controlled study. J Clin Oncol. 2010;28(24):3824-9.

Lountzis NI, Maroon MS. Sorafenib-induced palmoplantar hyperkeratosis. Journal of drugs in dermatology: JDD. 2008;7(6):588-9.